Additional small-scale studies have also indicated signs of clinical activity for T-DM1 in patients with HER2-positive MBC and BM [5]. These findings underscore the potential efficacy of T-DM1 as a treatment option for patients with HER2-positive breast cancer, especially those with brain metastases. The gene discussed is ERBB2; the disease is breast carcinoma.